These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23686524)

  • 1. Dopamine agonist withdrawal syndrome: implications for patient care.
    Nirenberg MJ
    Drugs Aging; 2013 Aug; 30(8):587-92. PubMed ID: 23686524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist withdrawal syndrome in Parkinson disease.
    Rabinak CA; Nirenberg MJ
    Arch Neurol; 2010 Jan; 67(1):58-63. PubMed ID: 20065130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic.
    Pondal M; Marras C; Miyasaki J; Moro E; Armstrong MJ; Strafella AP; Shah BB; Fox S; Prashanth LK; Phielipp N; Lang AE
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):130-5. PubMed ID: 22933817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson disease treatment center.
    Patel S; Garcia X; Mohammad ME; Yu XX; Vlastaris K; O'Donnell K; Sutton K; Fernandez HH
    J Neurol Sci; 2017 Aug; 379():308-311. PubMed ID: 28716269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonist withdrawal syndrome: A comprehensive review.
    Yu XX; Fernandez HH
    J Neurol Sci; 2017 Mar; 374():53-55. PubMed ID: 28104232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease.
    Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM
    Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience.
    Limotai N; Oyama G; Go C; Bernal O; Ong T; Moum SJ; Bhidayasiri R; Foote KD; Bowers D; Ward H; Okun MS
    Int J Neurosci; 2012 Mar; 122(3):145-53. PubMed ID: 22023411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasagiline Withdrawal Syndrome in Parkinson's Disease.
    Solla P; Ercoli T; Masala C; Orofino G; Fadda L; Corda DG; Zarbo IR; Meloni M; Sechi E; Bagella CF; Defazio G
    Brain Sci; 2022 Feb; 12(2):. PubMed ID: 35203982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of dopaminergic medication withdrawal in Parkinson's disease.
    Koschel J; Ray Chaudhuri K; Tönges L; Thiel M; Raeder V; Jost WH
    J Neural Transm (Vienna); 2022 Sep; 129(9):1169-1178. PubMed ID: 34324057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine 'switch'.
    Edwards MJ
    J Neurol Neurosurg Psychiatry; 2013 Feb; 84(2):120. PubMed ID: 22993451
    [No Abstract]   [Full Text] [Related]  

  • 12. Impulse control and related disorders in Parkinson's disease.
    Weintraub D; Nirenberg MJ
    Neurodegener Dis; 2013; 11(2):63-71. PubMed ID: 23038208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome.
    Voon V; Schoerling A; Wenzel S; Ekanayake V; Reiff J; Trenkwalder C; Sixel-Döring F
    BMC Neurol; 2011 Sep; 11():117. PubMed ID: 21955669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Prospective, Multicenter Observational Study of Dopamine Agonist Withdrawal Syndrome in Parkinson's Disease.
    Chaudhuri KR; Todorova A; Nirenberg MJ; Parry M; Martin A; Martinez-Martin P; Rizos A; Henriksen T; Jost W; Storch A; Ebersbach G; Reichmann H; Odin P; Antonini A
    Mov Disord Clin Pract; 2015 Jun; 2(2):170-174. PubMed ID: 30713891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease.
    Stocchi F; Fossati B; Torti M
    Expert Opin Drug Saf; 2020 Sep; 19(9):1155-1172. PubMed ID: 32869676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease.
    Kimber TE; Thompson PD; Kiley MA
    J Clin Neurosci; 2008 Feb; 15(2):205-8. PubMed ID: 18068992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine Agonist Withdrawal Syndrome and Suicidality in Parkinson's Disease.
    Kwan C; Kolivakis T; Huot P
    Can J Neurol Sci; 2023 Sep; 50(5):779-780. PubMed ID: 35801613
    [No Abstract]   [Full Text] [Related]  

  • 18. Introduction to Parkinson disease (PD) and its complications.
    Marvanova M
    Ment Health Clin; 2016 Sep; 6(5):229-235. PubMed ID: 29955475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review.
    Garcia X; Mohammad ME; Patel S; Yu XX; Fernandez HH
    Clin Park Relat Disord; 2022; 7():100153. PubMed ID: 35909701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication-related impulse control and repetitive behaviors in Parkinson's disease.
    Voon V; Potenza MN; Thomsen T
    Curr Opin Neurol; 2007 Aug; 20(4):484-92. PubMed ID: 17620886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.